Entero Therapeutics, Inc. (ENTO)
NASDAQ: ENTO · Real-Time Price · USD
0.540
+0.009 (1.69%)
At close: Jan 17, 2025, 4:00 PM
0.570
+0.030 (5.56%)
After-hours: Jan 17, 2025, 7:24 PM EST
Entero Therapeutics Employees
Entero Therapeutics had 9 employees as of December 31, 2023. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
-$1,127,763
Market Cap
2.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
ENTO News
- 2 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - Accesswire
- 2 months ago - ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO - Business Wire
- 2 months ago - Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company - GlobeNewsWire
- 3 months ago - Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board - Business Wire
- 5 months ago - Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - GlobeNewsWire
- 6 months ago - Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - GlobeNewsWire
- 7 months ago - Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease - GlobeNewsWire
- 8 months ago - Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention - GlobeNewsWire